I liked the article, gave a nice high level overview of what CYDY is all about, the possible reward, and possible pitfalls that could bring CYDY down. As always there will be a commenter who brings up that more should have been in the article, but I don't think the author follows CYDY as religiously as most, delves deep into all possible indications of CCR5 inhibitors, or has listened to all the conference calls/provestor interviews, but for an article to be short, and concise and give potential investors some info, its pretty decent.